An observational study in Systemic Lupus Erythematosus (SLE), sponsored by Patan Academy of Health Sciences. Completed at 1 site in Nepal. Per ClinicalTrials.gov, last updated 2025-04-20.
Sponsored by Patan Academy of Health Sciences · Observational
The goal of this observational study is to evaluate hematological abnormalities among patients with systemic lupus erythematosus (SLE) admitted to a tertiary care center in Nepal. The main question it aims to answer is:
The study retrospectively reviews medical records of SLE patients admitted between April 2018 and March 2023 to collect data on hematologic parameters, demographic profiles, clinical manifestations.
1,207 studies on the registry are indexed under Lupus Erythematosus, Systemic; 405 are open to participants now.
This study's enrollment of 99 is below the median of 151 across 280 observational studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Patan Academy of Health Sciences is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients admitted with diagnosis of systemic lupus erythematosus in medical ward of Patan Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with systemic lupus erythematosus as per 2019 European League of Associations for Rheumatology and American College of Rheumatology (2019 EULAR/ACR) criteria
Percentage of patients with hematological abnormalities
Anemia was defined as a Hb of less than 13 g/dL in males and less than 12 g/dL in females. Leukopenia was defined as a WBC of less than 4000 per cubic millimeter (cu.mm). Thrombocytopenia was defined as a platelet count of less than 100,000 per cubic millimeter. Lymphopenia and neutropenia were defined as absolute lymphocyte count less than 1500 per cu.mm and absolute neutrophil count less than 1800 per cu.mm.
Time frame: Baseline at the time of hospital admission. (Cross-sectional)
Percentage of SLE patients with mucocutaneous involvement
Proportion of patients exhibiting at least one mucocutaneous manifestation (malar rash, discoid rash, alopecia, or oral ulcers) based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through study completion from 2019 January to 2023 December.
Percentage of SLE patients with pericarditis
Proportion of patients exhibiting pericarditis based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with respiratory involvement
Proportion of patients exhibiting respiratory involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with gastrointestinal involvement
Proportion of patients exhibiting gastrointestinal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with kidney involvement
Proportion of patients exhibiting kidney involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with musculoskeletal involvement
Proportion of patients exhibiting musculoskeletal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with neurological involvement
Proportion of patients exhibiting neurological involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Plan to share: No
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Patan Academy of Health Sciences